NASDAQ:MEDP - Medpace Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$45.24 +0.26 (+0.58 %)
(As of 06/17/2018 04:00 PM ET)
Previous Close$45.24
Today's Range$44.09 - $45.89
52-Week Range$26.56 - $45.89
Volume462,718 shs
Average Volume386,367 shs
Market Capitalization$1.61 billion
P/E Ratio29.76
Dividend YieldN/A

About Medpace (NASDAQ:MEDP)

Medpace logoMedpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas. Its clinical development services include medical affairs, clinical trial management, feasibility and start-up study, clinical monitoring, global regulatory affairs, medical writing, biometrics, pharmacovigilance, core laboratory, and quality assurance. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.

Receive MEDP News and Ratings via Email

Sign-up to receive the latest news and ratings for MEDP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research


Debt-to-Equity Ratio0.41
Current Ratio0.66
Quick Ratio0.66


Trailing P/E Ratio29.76
Forward P/E Ratio23.94
P/E Growth1.71

Sales & Book Value

Annual Sales$436.15 million
Price / Sales3.69
Cash Flow$2.6287 per share
Price / Cash17.21
Book Value$13.40 per share
Price / Book3.38


EPS (Most Recent Fiscal Year)$1.52
Net Income$39.12 million
Net Margins10.37%
Return on Equity12.50%
Return on Assets7.08%


Outstanding Shares35,530,000

Medpace (NASDAQ:MEDP) Frequently Asked Questions

What is Medpace's stock symbol?

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

How were Medpace's earnings last quarter?

Medpace Holdings Inc (NASDAQ:MEDP) posted its quarterly earnings results on Monday, April, 30th. The company reported $0.60 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.43 by $0.17. The company had revenue of $108.40 million for the quarter, compared to analysts' expectations of $113.12 million. Medpace had a return on equity of 12.50% and a net margin of 10.37%. The firm's revenue was up 15.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.34 earnings per share. View Medpace's Earnings History.

When is Medpace's next earnings date?

Medpace is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for Medpace.

What guidance has Medpace issued on next quarter's earnings?

Medpace issued an update on its FY18 earnings guidance on Monday, April, 30th. The company provided EPS guidance of $1.87-1.97 for the period, compared to the Thomson Reuters consensus estimate of $1.88. The company issued revenue guidance of $421-435 million, compared to the consensus revenue estimate of $463.04 million.

What price target have analysts set for MEDP?

8 brokers have issued 1 year price targets for Medpace's shares. Their predictions range from $35.00 to $42.00. On average, they anticipate Medpace's stock price to reach $37.40 in the next twelve months. View Analyst Ratings for Medpace.

Are investors shorting Medpace?

Medpace saw a decline in short interest in the month of May. As of May 15th, there was short interest totalling 267,456 shares, a decline of 47.9% from the April 30th total of 512,869 shares. Based on an average daily trading volume, of 536,998 shares, the days-to-cover ratio is presently 0.5 days. Currently, 2.3% of the company's shares are short sold.

Who are some of Medpace's key competitors?

Who are Medpace's key executives?

Medpace's management team includes the folowing people:
  • Dr. August James Troendle, Chairman, Pres & CEO (Age 62)
  • Mr. Jesse J. Geiger, CFO & Chief Operating Officer of Laboratory Operations (Age 44)
  • Ms. Susan E. Burwig, Exec. VP of Operations (Age 55)
  • Mr. Stephen P. Ewald, Gen. Counsel & Corp. Sec. (Age 49)
  • Mr. Todd Meyers, VP of Bus. Devel. and Marketing

When did Medpace IPO?

(MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

Has Medpace been receiving favorable news coverage?

Media headlines about MEDP stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Medpace earned a media sentiment score of 0.10 on Accern's scale. They also assigned headlines about the company an impact score of 46.61 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are Medpace's major shareholders?

Medpace's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include CINVEN CAPITAL MANAGEMENT (V) GENERAL PARTNER LTD (37.70%), BlackRock Inc. (3.42%), Bernzott Capital Advisors (1.95%), UBS Group AG (0.91%), Granite Investment Partners LLC (0.73%) and Prudential Financial Inc. (0.50%). Company insiders that own Medpace stock include August J Troendle, Medpace Limited Partnership and Susan E Burwig. View Institutional Ownership Trends for Medpace.

Which institutional investors are selling Medpace stock?

MEDP stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Alambic Investment Management L.P., Hsbc Holdings PLC, Federated Investors Inc. PA, Granite Investment Partners LLC, Thrivent Financial for Lutherans, Bernzott Capital Advisors and Wells Fargo & Company MN. View Insider Buying and Selling for Medpace.

Which institutional investors are buying Medpace stock?

MEDP stock was purchased by a variety of institutional investors in the last quarter, including UBS Group AG, Dimensional Fund Advisors LP, American Century Companies Inc., Prudential Financial Inc., BlackRock Inc., Russell Investments Group Ltd., Allianz Asset Management GmbH and Allianz Asset Management GmbH. Company insiders that have bought Medpace stock in the last two years include August J Troendle and Susan E Burwig. View Insider Buying and Selling for Medpace.

How do I buy shares of Medpace?

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Medpace's stock price today?

One share of MEDP stock can currently be purchased for approximately $45.24.

How big of a company is Medpace?

Medpace has a market capitalization of $1.61 billion and generates $436.15 million in revenue each year. The company earns $39.12 million in net income (profit) each year or $1.52 on an earnings per share basis. Medpace employs 2,500 workers across the globe.

How can I contact Medpace?

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]

MarketBeat Community Rating for Medpace (MEDP)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  144 (Vote Outperform)
Underperform Votes:  130 (Vote Underperform)
Total Votes:  274
MarketBeat's community ratings are surveys of what our community members think about Medpace and other stocks. Vote "Outperform" if you believe MEDP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MEDP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/17/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.